<DOC>
	<DOCNO>NCT00542295</DOCNO>
	<brief_summary>To assess effectiveness alverine citrate simeticone IBS symptom accord late recommended design</brief_summary>
	<brief_title>Efficacy Safety MeteospasmylÂ® Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<criteria>male female ambulatory patient , age 1875 year IBS define Rome III criterion Functional bowel disorder IBS , Underlying cause symptomatology , exclude IBS diagnosis , Gastrointestinal cancer significant gastrointestinal surgical background , Any acute/uncontrolled systemic pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>